ACT |
Adaptive cell transfer |
ANOVA |
Analysis of variance |
APLCNR |
Apelin receptor |
C3 |
Complement component 3 |
CAR |
Chimeric antigen receptor |
CCL |
Chemokine antigen receptor |
CD137 |
Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) |
CD4+ cell |
Cluster of differentiation 4-positive cell |
CD8+ cell |
Cluster of differentiation 8-positive cell |
CRISPR |
Clustered regularly interspaced short palindromic repeats |
CTLA-4 |
Cytotoxic T-lymphocyte-associated protein 4 |
CX3CR1 |
CX3C chemokine receptor |
CXCL13 |
Chemokine (C-X-C motif) ligand 13 |
cyTOF |
Mass cytometry |
dMMR |
Deficient DNA mismatch repair |
EGFR |
Epidermal growth factor receptor |
EI |
Electron impact |
ESI |
Electrospray ionization |
GC |
Gas chromatography |
GCMB |
Glial Cells Missing Transcription Factor 2 |
GEO |
Gene Expression Omnibus |
GITR |
Glucocorticoid-induced TNFR family-related gene |
GZMK |
Granzyme K |
HOPE |
High-tech Omics-based Patient Evaluation |
IARC |
International Agency for Research on Cancer |
ICGC |
International Cancer Genome Consortium |
ICI |
Immune checkpoint inhibitor |
IDO |
Indoleamine 2,3-dioxygenase |
IFN |
Interferon |
IL |
Interleukin |
IL17RA |
IL17 receptor A |
irAE |
Immune-related adverse event |
LC |
Liquid chromatography |
LIHC |
Liver hepatocellular carcinoma |
MS |
Mass spectrometry |
MS/MS |
Tandem mass spectrometry |
MSI |
Microsatellite instability |
NGS |
Next-generation sequencing |
NIST |
National Institute of Standards and Technology |
NK |
Natural killer cell |
nSMase2 |
Sphingomyelinase 2 |
OX40 |
Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4) |
PCA |
Principal component analysis |
PCR |
Polymerase chain reaction |
PD-1 |
Programmed cell death protein 1 |
PD-L1 |
Programmed death-ligand 1 |
PEG |
Polyethylene glycol |
PLA2G4A |
Phospholipase A2 group IVA |
PLS-DA |
Partial least squares-discriminant analysis |
POLE |
Polymerase epsilon |
PRF1 |
Perforin 1 |
PTGS2 |
Prostaglandin-endoperoxide synthase 2 |
PTPN2 |
Protein Tyrosine Phosphatase Non-Receptor Type 2 |
TCF7 |
Transcription Factor 7 |
TCGA |
The Cancer Genome Atlas |
TCPA |
The Cancer Proteome Atlas |
TDO |
Tryptophan 2,3-dioxygenase |
TMB |
Tumor mutation burden |
TME |
Tumor microenvironment |
VEGFA |
Vascular endothelial growth factor A |
VISTA |
v-domain Ig suppressor of T-cell activation |
VLCFA |
Very-long-chain fatty acid |
VOC |
Volatile organic compound |
WGS |
Whole-genome sequencing |
WHO |
World Health Organization |